Showing results (1-10 of 57) with videos related to
Sort By:
Pageof 6
Chronic Stress (Thousand Oaks, Calif.)|October 24, 2022
(Es)Ketamine for Suicidal Ideation and Behavior: Clinical EfficacyAlexandra A Alario, Mark J NiciuChronic Stress (Thousand Oaks, Calif.)|June 23, 2021
Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiologyAlexandra A Alario, Mark J NiciuCNS Drugs|July 25, 2013
Targeted opioid receptor antagonists in the treatment of alcohol use disordersMark J Niciu, Albert J AriasCurrent Behavioral Neuroscience Reports|March 29, 2014
Neuroimaging in Alcohol and Drug DependenceMark J Niciu, Graeme F MasonPharmacology, Biochemistry, and Behavior|September 6, 2011
Overview of glutamatergic neurotransmission in the nervous systemMark J Niciu, Benjamin Kelmendi, Gerard SanacoraCurrent Behavioral Neuroscience Reports|January 30, 2016
Novel Glutamatergic Treatments for Severe Mood DisordersMinkyung Park, Mark J Niciu, Carlos A ZarateChronic Stress (Thousand Oaks, Calif.)|September 13, 2019
Neurophysiological Correlates and Differential Drug Response in Subjects With a Family History of an Alcohol Use DisorderSage M Comstock, Jatin G Vaidya, Mark J NiciuCNS Drugs|April 21, 2015
Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disordersChristopher J Hammond, Mark J Niciu, Shannon Drew, et al.The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|September 13, 2013
Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?Mark J Niciu, Ioline D Henter, Gerard Sanacora, et al.The Primary Care Companion for CNS Disorders|October 16, 2014
Pharmacologic treatment of dimensional anxious depression: a reviewDawn F Ionescu, Mark J Niciu, Erica M Richards, et al.Pageof 6